IDYA

IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's approach involves identifying and targeting specific genetic mutations and pathways that drive tumor growth in cancer patients. IDEAYA's pipeline includes programs targeting synthetic lethality mechanisms, including PARP inhibitors, MAT2A inhibitors, and Pol Theta inhibitors, as well as other precision oncology approaches. The company collaborates with leading pharmaceutical and biotechnology companies to advance its programs and employs biomarker-driven clinical trial designs to identify patients most likely to benefit from its therapies.